Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

NCT00003207

completedphase_1

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

NCT00001570

completedphase_1

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

NCT00001383

completedphase_1

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302

Clinical Trials (4)

Showing 4 of 4 trials

NCT00003207Phase 1

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Completed

NCT00001570Phase 1

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

Completed

NCT00001383Phase 1

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

Completed

NCT00001302Phase 1

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4